Table 2:
Overview of included EWAS, their phenotypes (allergy-related outcome) and age groups.
| EWAS | Phenotype | No. of significant CpGs with FDR- corrected p- values <0.05[with raw p-values <0.011] |
Sample size (discovery + replication) |
Age | Ethnicity | P-value threshold for best MRS2 |
No. of included CpGs (best MRS) |
Cohorts | Chip |
|---|---|---|---|---|---|---|---|---|---|
| Everson2015 6 | Atopy status (IgE >= 200kU/L) | 13 | 367 + 464 | 18 | European | 1×10−8 | 2 | IoW + BAMSE | 450K |
| Chen2017 7 | Log10(IgE) | 200 [25 089] | 879 (meta) | 6 to 22 | Hispanic | 1×10−8 | 3 | PR-GOAL, GALA II | 450K |
| Peng2019 8 | Environmental allergen sensitization (>= 0.35 IU/ml to common aeroallergens) | 395 | 739 (total) | mean: 7.7 & 9.8 | Multi-ethnic | 1×10−13 | 5 | Project Viva, Generation R | 450K |
| Zhang2019 9 | Atopic status (>= 3mm grater than negative control in SPT or IgE >= 0.35 kU/L for mix inhalant of food allergens) | 35 [775] | 376 + 267 | 10 & 18 | European | 1×10−4 | 24 | IoW + BAMSE | 450K/EPIC |
| Reese2019 10 | Childhood asthma | 179 | 3493 (meta) | mean range: 7.1 to 17.01 | Multi-Ethnic | 1×10−8 | 9 | BAMSE, CHOP, GALA II, ICAC, NFBC 1986, PIAMA, RAINE, STOPPA | 450K |
| Xu2021 11 | Any allergic disease (asthma, eczema, rhinitis) PLUS sensitization against common aeroallergens (>= 0.35IU/ml) | 21 | 1457 + 1436 | 4 & 8 | European | 1×10−9 | 18 | BAMSE, INMA, PIAMA + EDEN, ECA, INMA, PIAMA, Karelia | 450K |
| Hannon2016 34 | Schizophrenia (negative control) | 2519 | 675 + 847 | Adults | European | 1×10−5 | 867 | UCL case-control + Aberdeen case-control, MZ twins cohort | 450K |
1
some studies provided additional summary statistics for all CpG sites with p-values < 0.01, n/a indicates that these additional summary statistics were not provided
2
best MRS per EWAS were selected based on the highest c-statistic in the cross-sectional model at six years across all p-value thresholds that were tested (see also Table S2, where all MRS are evaluated)